Aggrenox® (aspirin/extended-release dipyridamole) 25 mg/200 mg capsules is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

Menu

In ESPS 2...

91% Of Patients on AGGRENOX Remained Stroke Free for 2 Years

Consider AGGRENOX for your patients with prior TIA or ischemic stroke to help reduce the risk of subsequent stroke1

1 Learn more

ESPS 2=European Stroke Prevention Study 2; TIA=transient ischemic attack.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

Aggrenox® (aspirin/extended-release dipyridamole) 25 mg/200 mg capsules is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

IMPORTANT SAFETY INFORMATION

AGGRENOX is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drugs (NSAIDs) and in patients with the syndrome of asthma, rhinitis, and nasal polyps. AGGRENOX is contraindicated in patients with hypersensitivity to any of its ingredients.

AGGRENOX increases the risk of bleeding. Co-administration with anticoagulants, antiplatelets, or NSAIDs can increase risk of bleeding. AGGRENOX should be avoided in patients with peptic ulcer disease or those having coagulation abnormalities. Patients who consume three or more alcoholic drinks daily should be counseled about the risk of increased bleeding.

AGGRENOX should be avoided during pregnancy due to the potential risk to the fetus. AGGRENOX should be avoided in patients with severe hepatic or renal insufficiency. Decreased renal function can occur with co-administration with NSAIDs.

The most frequently reported adverse reactions (>10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea.

Please see the full AGGRENOX Prescribing Information.

IMPORTANT SAFETY INFORMATION

EXPAND SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

Aggrenox® (aspirin/extended-release dipyridamole) 25 mg/200 mg capsules is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

IMPORTANT SAFETY INFORMATION

AGGRENOX is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drugs (NSAIDs) and in patients with the syndrome of asthma, rhinitis, and nasal polyps. AGGRENOX is contraindicated in patients with hypersensitivity to any of its ingredients.

AGGRENOX increases the risk of bleeding. Co-administration with anticoagulants, antiplatelets, or NSAIDs can increase risk of bleeding. AGGRENOX should be avoided in patients with peptic ulcer disease or those having coagulation abnormalities. Patients who consume three or more alcoholic drinks daily should be counseled about the risk of increased bleeding.

AGGRENOX should be avoided during pregnancy due to the potential risk to the fetus. AGGRENOX should be avoided in patients with severe hepatic or renal insufficiency. Decreased renal function can occur with co-administration with NSAIDs.

The most frequently reported adverse reactions (>10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea.

Please see the full AGGRENOX Prescribing Information.